OptimizeRx Lowers FY2026 Sales Guidance from $95.000M-$100.000M to $87.000M-$93.000M vs $96.230M Est
Benzinga Newsdesk 4 hours ago
NewsGuidance
OptimizeRx (NASDAQ:OPRX) lowers FY2026 sales outlook from $95.000 million-$100.000 million to $87.000 million-$93.000 million vs $96.230 million estimate.
OptimizeRx (NASDAQ:OPRX) lowers FY2026 sales outlook from $95.000 million-$100.000 million to $87.000 million-$93.000 million vs $96.230 million estimate.